Earnings results for Cytosorbents (NASDAQ:CTSO)
Cytosorbents Corporation is expected* to report earnings on 11/04/2020 after market close. The report will be for the fiscal Quarter ending Sep 2020. According to Zacks Investment Research, based on 6 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.09. The reported EPS for the same quarter last year was $-0.21.
Cytosorbents last released its quarterly earnings results on August 4th, 2020. The medical research company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08). The firm had revenue of $9.80 million for the quarter, compared to analyst estimates of $9.79 million. Cytosorbents has generated ($0.60) earnings per share over the last year. Cytosorbents has confirmed that its next quarterly earnings report will be published on Wednesday, November 4th, 2020.
Analyst Opinion on Cytosorbents (NASDAQ:CTSO)
6 Wall Street analysts have issued ratings and price targets for Cytosorbents in the last 12 months. Their average twelve-month price target is $15.17, predicting that the stock has a possible upside of 75.95%. The high price target for CTSO is $17.00 and the low price target for CTSO is $14.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Cytosorbents has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $15.17, Cytosorbents has a forecasted upside of 75.9% from its current price of $8.62. Cytosorbents has only been the subject of 2 research reports in the past 90 days.
Dividend Strength: Cytosorbents (NASDAQ:CTSO)
Cytosorbents does not currently pay a dividend. Cytosorbents does not have a long track record of dividend growth.
Insiders buying/selling: Cytosorbents (NASDAQ:CTSO)
In the past three months, Cytosorbents insiders have not sold or bought any company stock. Only 5.70% of the stock of Cytosorbents is held by insiders. Only 26.11% of the stock of Cytosorbents is held by institutions.
Earnings and Valuation of Cytosorbents (NASDAQ:CTSO
Earnings for Cytosorbents are expected to grow in the coming year, from ($0.34) to ($0.11) per share. The P/E ratio of Cytosorbents is -16.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Cytosorbents is -16.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Cytosorbents has a P/B Ratio of 78.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here